Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung.

The oncologist - 1 Jan 2013

Heist Rebecca, Azzoli Christopher G

Abstract excerpt

After routine staging tests, including a FDG-PET scan and MRI of the brain, a 59-year-old mother of four, never smoker, undergoes uncomplicated right lower lobectomy of the lung to remove a 3.9 cm adenocarcinoma with visceral pleural invasion (pIB,T2N0M0). Should she receive adjuvant chemotherapy? If so, what drug, dose, and schedule?

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Smoking

Source

Open in PubMed Open full text

Identifiers

PMID: 24277772
DOI: 10.1634/theoncologist.2013-0297
PMCID: PMC3868419

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung.PMID 24277772Read ↗

A phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesotheliomaSemantic proximity Read ↗

Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.Semantic proximity Read ↗

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.Semantic proximity Read ↗

First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation.Semantic proximity Read ↗

Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary managementSemantic proximity Read ↗

EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.